- 专利标题： SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS
-
申请号： EP21315226.7申请日： 2021-10-25
-
公开(公告)号： EP4169904A1公开(公告)日： 2023-04-26
- 发明人: Houacine, Jemila , Dao, Pascal , Passeron, Thierry , Beranger, Guillaume , Benhida, Rachid , Gourhant, Mathilde , Foussat, Arnaud
- 申请人： Yukin Therapeutics , Institut National de la Santé et de la Recherche Médicale (INSERM) , Centre Hospitalier Universitaire de Nice (CHU Nice) , Université Côte d'Azur , Centre National de la Recherche Scientifique (CNRS)
- 申请人地址： FR 06902 Sophia Antipolis Cedex 291 rue Albert Caquot CS4009; FR 75013 Paris 101 rue de Tolbiac; FR 06000 Nice 4 Avenue de la Reine Victoria; FR 06103 Nice Cedex 2 Grand Château 28 Avenue Valrose; FR 75016 Paris 3, rue Michel Ange
- 代理机构： Vossius & Partner Patentanwälte Rechtsanwälte mbB
- 主分类号： C07D215/44
- IPC分类号： C07D215/44 ; C07D401/04 ; A61P35/00 ; C07D401/12 ; C07D405/12 ; C07D409/12 ; C07D417/04 ; C07D487/08 ; C07D487/10 ; A61K31/4706 ; A61P37/00
摘要：
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as NF-κB-inducing kinase (NIK) inhibitors and, in particular, can induce the intracellular degradation of NIK, which renders these compounds highly advantageous for use in therapy, including in the treatment or prevention of cancer, inflammatory diseases and autoimmune diseases.
信息查询
